New CAR T Cell Treatment for Acute Myeloid Leukemia
Project 4: Chimeric Antigen Receptor T Cell Therapy for the Treatment of Acute Myeloid Leukemia
This research explores a new type of cell therapy that uses specially designed immune cells to fight acute myeloid leukemia.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11124249 on NIH RePORTER |
What this research studies
Acute myeloid leukemia (AML) often requires new treatment options, especially those that can target the leukemia stem cells that cause the disease to return. This therapy focuses on a specific marker called CD371, which is found on AML cells and their stem cells but not on healthy blood stem cells. Researchers have developed a special type of immune cell, called a CAR T cell, that is designed to find and attack cells with the CD371 marker. These CAR T cells are also engineered to release a substance called IL-18, which is expected to help the CAR T cells work better and longer, and also activate other immune cells to fight the cancer. The hope is that this approach will effectively eliminate leukemia cells, including those that are resistant to standard chemotherapy.
Who could benefit from this research
Good fit: This research is focused on adult patients, 21 years and older, with acute myeloid leukemia.
Not a fit: Patients whose leukemia cells do not express the CD371 marker may not benefit from this specific targeted therapy.
Why it matters
Potential benefit: If successful, this therapy could offer a new and more effective way to treat acute myeloid leukemia, especially for patients whose disease is resistant to current treatments.
How similar studies have performed: CAR T cell therapies have shown success in other blood cancers, but this specific CD371-targeted, IL-18-secreting approach is novel and still in development.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Brentjens, Renier Joseph — Sloan-Kettering Inst Can Research
- Study coordinator: Brentjens, Renier Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.